{"product_id":"ikanggroup-five-forces-analysis","title":"iKang Group Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eiKang Group faces moderate supplier power, strong buyer sensitivity to price and quality, and intense rivalry amid digital health entrants and incumbents, while regulatory shifts and substitution from telemedicine shape strategic risks.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore iKang Group’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Medical Equipment Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary suppliers for iKang are global and domestic medical device giants supplying MRI, CT, and ultrasound systems, with the top five vendors controlling roughly 70–80% of the high-end diagnostic market in China as of 2025. These specialized machines need regular maintenance and software updates, so dominant manufacturers exert strong leverage over pricing, spare parts, and multi-year service contracts, often locking clinics into 10–15% annual service fees. By end-2025, China's push in domestic high-tech medical manufacturing raised local suppliers' share to about 30–35%, slightly reducing foreign vendors' pricing power but leaving high-end tech still concentrated among a few players. For iKang, supplier bargaining power remains high, especially for cutting-edge MRI and PET-CT units that cost $1–4 million each and have scarce local equivalents.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Specialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQualified medical professionals—radiologists and specialized physicians—are core to iKang Group’s services, driving diagnosis and treatment quality.\u003c\/p\u003e\n\u003cp\u003eChina’s private sector faces a shortage: in 2023, urban tertiary hospitals had 2.9 physicians per 1,000 people versus 2.0 in private clinics, boosting clinicians’ bargaining power on pay and hours.\u003c\/p\u003e\n\u003cp\u003eiKang must offer competitive packages—salaries, signing bonuses, profit-sharing—to retain staff and avoid losses to public hospitals or rivals; headcount turnover rose ~12% in 2024, raising labor costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Reagent and Consumable Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiagnostic testing needs steady chemical reagents and consumables; China’s procurement platforms have concentrated 60%+ of reagent purchases among top five distributors by 2024, letting suppliers keep prices steady.\u003c\/p\u003e\n\u003cp\u003eiKang Group’s network drove reagent spend reductions of about 8–12% through volume contracts in 2023, yet its scale still ties it to preferred supplier lists.\u003c\/p\u003e\n\u003cp\u003eBecause reagents are mission-critical, iKang faces switching costs and operational risk if suppliers change, limiting bargaining despite discounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIT and Digital Infrastructure Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs iKang expands AI and cloud health systems, reliance on specialized software and data-security vendors has risen; globally, healthcare cloud spending hit about $48B in 2024, concentrating supplier clout.\u003c\/p\u003e\n\u003cp\u003eSwitching costs are very high—complex data migration and regulatory revalidation can take 6–12 months and cost millions—so suppliers gain leverage.\u003c\/p\u003e\n\u003cp\u003eThe small pool of healthcare-compliant cloud providers (top 5 hold ~70% market share) further limits alternatives, raising supplier bargaining power.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHealthcare cloud market ≈ $48B (2024)\u003c\/li\u003e\n\u003cli\u003eTop 5 providers ≈70% share\u003c\/li\u003e\n\u003cli\u003eMigration 6–12 months, $M+ costs\u003c\/li\u003e\n\u003cli\u003eHigh regulatory revalidation risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal Estate and Facility Landlords\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiKang runs ~2,800 physical medical centers, many in Tier 1\/2 city commercial districts, so landlords hold strong leverage at lease renewal given limited alternative sites and strict medical zoning.\u003c\/p\u003e\n\u003cp\u003eRents in prime Chinese business districts rose ~6–9% YoY in 2024, making iKang sensitive to rental inflation that can compress margins and raise operating costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~2,800 centers nationwide\u003c\/li\u003e\n\u003cli\u003eTier 1\/2 location concentration\u003c\/li\u003e\n\u003cli\u003e2024 prime rent up 6–9% YoY\u003c\/li\u003e\n\u003cli\u003eStrict medical zoning limits relocation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh supplier concentration, rising domestic share, clinician scarcity drives cost and lock-in\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high: top device vendors control ~70–80% of high-end diagnostic kit (MRI\/PET-CT $1–4M), domestic share rose to ~30–35% by end-2025; reagents: top 5 distributors ≈60%+; healthcare cloud ≈$48B (2024) with top 5 ≈70% share; skilled clinicians scarce (2.0 private vs 2.9 public per 1,000 in 2023), turnover ~12% in 2024—raising costs and lock-in risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh-end devices\u003c\/td\u003e\n\u003ctd\u003e70–80% market concentration; $1–4M\/unit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic suppliers\u003c\/td\u003e\n\u003ctd\u003e30–35% share (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eTop5 ≥60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud\u003c\/td\u003e\n\u003ctd\u003e$48B (2024); top5 ≈70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003e2.0 vs 2.9\/1,000; turnover ~12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for iKang Group, this Porter’s Five Forces overview uncovers competitive intensity, buyer and supplier leverage, substitution risks, and entry barriers—highlighting disruptive threats and strategic levers that influence pricing, profitability, and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for iKang Group—quickly spot competitive threats and opportunity zones to streamline strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominance of Corporate Client Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa large share of ikang healthcare group revenue comes from corporate accounts buying annual employee checkup packages in contracts made up about service giving clients strong volume-based bargaining power. employers can pressure for lower per-capita fees or added services squeezing margins gross margin on checkups fell to fy2024. if a major client defects rivals such as meinian onehealth which held market would face sizable and especially given high concentration.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreased Price Transparency for Individuals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividual consumers now compare prices and reviews on digital health platforms and review sites, making them more price-sensitive and informed.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, online price-comparison tools show up to 30% variance in package costs across providers, so individuals routinely shop for best value.\u003c\/p\u003e\n\u003cp\u003eThis transparency forces iKang Group to keep competitive pricing and maintain \u0026gt;95% service-quality scores to retain retail customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Health Checkups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLow switching costs for routine health checkups mean an average consumer or small employer can move from iKang to a rival with minimal friction, since annual exams are one-off transactions rather than long-term treatments; industry surveys show about 62% of Chinese consumers shop providers annually for checkups (2024), so iKang must constantly prove value via pricing, convenience, and loyalty programs to avoid revenue churn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Personalized and Digital Results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpmodern customers now expect integrated digital health records and personalized follow-up not just static reports shifting bargaining power to buyers who choose providers with superior ux ikang reported service revenue growth of forcing ongoing platform investment.\u003e\n\u003cpthis trend raises switching risk show of chinese patients prioritize mobile follow-up tools ikang must spend on it to retain volume and arpu.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 digital revenue +18%\u003c\/li\u003e\n\u003cli\u003e62% patients prefer mobile follow-up\u003c\/li\u003e\n\u003cli\u003eHigher UX = lower churn, higher ARPU\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pmodern\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Public Hospital Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePublic hospitals remain China's perceived gold standard for diagnostic accuracy, and by 2024 about 55% of urban inpatient revenue still flowed to public tertiary centers, making their VIP outpatient and private checkup expansions credible rivals to iKang.\u003c\/p\u003e\n\u003cp\u003eThose public-sector offerings cap iKang's pricing power—patients can switch back to state-run care—so iKang must match quality or compete on convenience and breadth rather than price hikes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e55% urban inpatient revenue at public tertiary hospitals (2024)\u003c\/li\u003e\n\u003cli\u003ePublic VIP\/private wings expanded in 2019–2023\u003c\/li\u003e\n\u003cli\u003eLimits iKang price increases; competition on service, not price\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiKang margin squeeze: corporate buyers dominate, digital pivot vital as churn risk rises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpmajor buyers accounted for of ikang service revenue in strong volume bargaining power pressuring fees and squeezing checkup gross margin to fy2024 a loss major client or share meinian onehealth market would materially hit revenue. retail customers face low switching costs online price variance up while patients prefer mobile follow-up forcing digital investment curb churn.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate share of revenue\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCheckup gross margin\u003c\/td\u003e\n\u003ctd\u003e≈28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMeinian market share\u003c\/td\u003e\n\u003ctd\u003e≈18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital revenue growth\u003c\/td\u003e\n\u003ctd\u003e+18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients preferring mobile follow-up\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline price variance\u003c\/td\u003e\n\u003ctd\u003eup to 30% (late 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pmajor\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eiKang Group Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of iKang Group you'll receive immediately after purchase—no surprises, no placeholders. The document is fully formatted, professionally written, and ready for download and use the moment you buy. It contains the complete competitive assessment, including threat of entrants, buyer and supplier power, threat of substitutes, and industry rivalry. You’ll get this identical file instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746844914041,"sku":"ikanggroup-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ikanggroup-five-forces-analysis.png?v=1772192410","url":"https:\/\/growthsharematrix.com\/products\/ikanggroup-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}